OSAKA -- Fujisawa Pharmaceutical Co. said Wednesday it has signed a licensing agreement with Dutch medical technology group Jomed NV in the field of medical equipment for treating cardiac disease.
Under the agreement, Fujisawa will give Jomed access to its immunosuppressant products. The Dutch firm will then develop new medical equipment coated with Fujisawa's products.
The equipment, slated to go on the European market in 2003, will be used for vascular operations to treat coronary occlusion and unstable angina, it added.